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Morpholino phosphorodiamidate antisense oligonucleotides (MOs) and short interfering RNAs (siRNAs) are commonly
used platforms to study gene function by sequence-specific knockdown. Both technologies, however, can elicit
undesirable off-target effects. We have used several model genes to study these effects in detail in the zebrafish, Danio
rerio. Using the zebrafish embryo as a template, correct and mistargeting effects are readily discernible through direct
comparison of MO-injected animals with well-studied mutants. We show here indistinguishable off-targeting effects
for both maternal and zygotic mRNAs and for both translational and splice-site targeting MOs. The major off-targeting
effect is mediated through p53 activation, as detected through the transferase-mediated dUTP nick end labeling assay,
acridine orange, and p21 transcriptional activation assays. Concurrent knockdown of p53 specifically ameliorates the
cell death induced by MO off-targeting. Importantly, reversal of p53-dependent cell death by p53 knockdown does not
affect specific loss of gene function, such as the cell death caused by loss of function of chordin. Interestingly,
quantitative reverse-transcriptase PCR, microarrays and whole-mount in situ hybridization assays show that MO off-
targeting effects are accompanied by diagnostic transcription of an N-terminal truncated p53 isoform that uses a
recently recognized internal p53 promoter. We show here that MO off-targeting results in induction of a p53-
dependent cell death pathway. p53 activation has also recently been shown to be an unspecified off-target effect of
siRNAs. Both commonly used knockdown technologies can thus induce secondary but sequence-specific p53
activation. p53 inhibition could potentially be applicable to other systems to suppress off-target effects caused by
other knockdown technologies.
Citation: Robu ME, Larson JD, Nasevicius A, Beiraghi S, Brenner C, et al. (2007) p53 activation by knockdown technologies. PLoS Genet 3(5): e78. doi:10.1371/journal.pgen.
0030078
Introduction
Morpholino phosphorodiamidate oligonucleotides (MOs)
[1] and short inhibitory RNAs (siRNAs) [2] have been
instrumental to induce sequence-speciﬁc gene knockdown
in multiple systems. However, the use of both technologies is
sometimes limited by induction of off-target effects [3–7].
About 15–20% of MOs used in zebraﬁsh show off-targeting
effects [3], represented by a signature neural death peaking at
the end of segmentation (1 day post-fertilization [dpf]). The
affected embryos grow with smaller heads and eyes, exhibit
somite and notochord abnormalities, and eventually display
craniofacial defects. These MO-induced developmental de-
fects are target-independent because they are not displayed
by characterized mutants in the respective genes [3].
We show here that the off-target effects of MOs are
mediated through p53-induced apoptosis. Concurrent knock-
down of p53 with various MOs signiﬁcantly alleviates off-
target neural death. Importantly, however, p53 MO did not
affect speciﬁc phenotypes induced by a variety of MOs. We
propose the use of p53 knockdown as a tool to attenuate off-
target effects and facilitate the study of speciﬁc loss of
function phenotypes.
Results
MOs Exhibit Off-Target Neural Apoptotic Effects
General morphological features of MO-induced off-target
neural death have been previously described [3]. We further
investigated the nature of this cell death and the mechanism
of MO mistargeting. For this report, we focused primarily on
MOs designed against two gene targets for which mutants
have been previously described, wnt5/pipetail (ppt) [8] and
smoothened/slow muscle omitted (smu) [9,10], to facilitate the
discrimination between speciﬁc and nonspeciﬁc effects. A
translational MO against smoothened (Smo MO) induces
characteristic smu phenotype (spinal curvature, U-shaped
somites) (Figure 1C). A splice-site wnt5 MO (Wnt5 MO1)
induces tail and body-axis shortening and somite compres-
sion (Figure 1E), characteristic of the wnt5/ppt mutant (Figure
1K). What both Smo MO- and Wnt5 MO-injected embryos
(morphants) have in common is an additional and very
similar neural death (Figure 1, arrows). This neural death is
target-independent, since it is not exhibited by the respective
mutants (Figure 1K) [9,10]. Nonetheless, this neural death
appears to be sequence-speciﬁc, since a completely different
splice-site wnt5 MO (Wnt5 MO2) shows no neural death, but
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1G). We tested another type of knockdown molecule based on
an alternating trans-4-hydroxy-L-proline/phosphate polya-
mide backbone called gripNA [11]. Interestingly, a gripNA
targeting wnt5 (similar in sequence to Wnt5 MO1) also
induces neural death along with the characteristic wnt5/ppt
phenotype (Figure 1I). A gripNA against smoothened also causes
additional neural death (unpublished data), supporting the
idea that the off-targeting effects are not limited to the MO
chemistry, but represent a common feature to these knock-
down technologies.
The off-target neural death induced by MOs is highly
reminiscent of the neural death induced by a published
Mdm2 MO (Figure 1M). Mdm2 is a negative regulator of the
tumor suppressor p53, the gene most frequently mutated in
human cancers [12]. Mdm2 knockout in mice is an embryonic
lethal [13] due to extensive p53 upregulation and p53-
induced apoptosis. Mdm2-targeted MO in zebraﬁsh was
reported to induce apoptotic neural death [14]. We examined
the mechanism of MO-induced off-target neural death by
testing for apoptosis in multiple MO-injected zebraﬁsh
embryos using a transferase-mediated dUTP nick end label-
ing (TUNEL) assay (Figure 2) and by staining with acridine
orange (unpublished data). Our results suggest that the neural
death induced by off-targeting MOs is apoptotic in nature
and was indistinguishable from the cell death observed in the
Mmd2 knockdown [14]. We tested the speciﬁcity of Mdm2
MO-induced cell death by overexpressing a Mdm2 RNA
construct. However, we did not observe any signiﬁcant rescue
of the Mdm2 MO-induced cell death with the Mdm2 RNA
construct (unpublished data). Therefore, it is possible that the
cell death phenotype induced by the Mdm2 MO is also
primarily an off-targeting effect. We performed an in-depth
analysis of MO off-targeting to examine the concordance
between the phenotypes observed by light microscopy and
apoptosis patterns observed by TUNEL staining. We analyzed
zebraﬁsh embryos injected with Wnt5 MO1 at 14 hpf (the
onset of cell death, [3]), 22 hpf, 26 hpf, and 30 hpf (Figures 3
and 4; Figure S1). Brightﬁeld images show the signature
appearance of opaque-looking discolored tissue around the
eyes and in the nervous system in embryos injected with Wnt5
MO1 (Figures 3 and 4; Figure S1). The extent of the opaque
tissue increased at later time points and with increasing MO
dose. The cell death could be more easily visualized using
darkﬁeld microscopy (Figures 3A, 3C, 3F, 3I, 3L, 3O, 3R, 3U,
3X, 4C, 4F, 4I, 4L, 4O, 4R, 4U, and 4X). This analysis shows the
Figure 1. p53 MO Attenuates Cell Death Induced by MOs and GripNAs
(A–G and I–N) Brightfield images of 28 hpf embryos injected with
demonstrative MOs and gripNAs. The arrows (C, E, I, and M) indicate
neural death that is significantly attenuated to normal head size and
morphology by co-knockdown of p53 (D, F, J, and N). Interestingly, Wnt5
MO2 shows no significant neural death (G) even at 6 ng, a higher dose
than Wnt5 MO1 (E) (3 ng), but can elicit a highly penetrant Wnt5
phenotype even at 1.5 ng (unpublished data).
(H) Effect of p53 MO on Wnt5 splicing. We carried out RT-PCR using
primers spanning the exon 5–exon 6 junction targeted by Wnt5 MO1.
Proper splicing was completely inhibited by Wnt5 MO1. p53 co-
knockdown did not affect the efficiency of Wnt5 MO1 inhibition.
Embryos injected with Wnt5 MO2, which targets the previous junction
(exon 4–exon 5), still exhibited some properly spliced transcript at the
exon 5–exon 6 junction. b-actin was used as a loading control.
doi:10.1371/journal.pgen.0030078.g001
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Author Summary
Recent advances in sequence-based approaches to ‘‘knockdown’’
gene function have opened the door to an array of approaches to
uncover functions for genes of interest. Vertebrate knockdown
strategies—such as morpholinos (MOs) in zebrafish or RNA
interference-based strategies in mammalian systems—have been
demonstrated to be effective, rapid, and cost-efficient reverse-
genetic approaches for studying gene function. However, their
deployment has to date been limited by a number of technical
(genomic, biological, and off-targeting) hurdles. One of the notable
and unexpected findings from our work using MOs has been a series
of observations surrounding unanticipated effects that are inde-
pendent of the intended gene target. We have identified and
characterized a recently described p53 induction pathway due to
off-targeting that appears to be shared between knockdown
technologies. This study reconciles a series of unexpected findings
that show p53 upregulation at the transcriptional level in a subset of
short inhibitory RNA- and MO-treated vertebrate systems. Moreover,
concurrent p53 knockdown provides a new approach to facilitate
the identification of previously hidden gene functions. This study
provides both a new gene knockdown enhancement tool as well as
additional insight into an important and conserved pathway
implicated in cellular toxicity.characteristic pattern of white tissue corresponding to the
opaque structures seen in brightﬁeld that is diagnostic of MO
mistargeting in zebraﬁsh embryos.
At 26 hpf, milder phenotypes displaying a characteristic
anterior-ventral concavity and/or hindbrain depression could
be observed, in the absence of the opaque/white tissue
characteristic of the more severe cases of cell death (Figure
4D–4F). However, when analyzed by TUNEL staining, we
observed that even the mild phenotypes (as seen by light
microscopy) were associated with signiﬁcant apoptosis
(Figure 4P–4R). These mildly affected embryos usually
recovered by 30 hpf, when they showed signiﬁcantly less cell
death, if any (unpublished data). The more severely affected
embryos did not recover until day 2 or 3, at which time the
characteristic apoptotic tissue was no longer apparent either
through light microscopy or TUNEL analysis (unpublished
data). However, these embryos lacked some neural tissue and
developed with smaller heads and eyes (unpublished data).
The punctuated pattern of neural apoptosis seen at all time
points and with increasing intensity in the more severe cases
was strikingly different from the normal apoptotic pattern
seen in uninjected control embryos (Figures 3 and 4).
Developmentally regulated apoptosis has been described in
detail [15] and was recapitulated by our analysis (Figures 3
and 4, uninjected embryos). However, at all studied time
points the extent of developmentally regulated apoptosis was
signiﬁcantly less extensive than the apoptosis induced by MO
off-targeting. In particular, at 30 hpf, little if any apoptosis
was noted in control embryos. Therefore, we performed the
TUNEL analysis at 30 hpf for all subsequent experiments to
clearly differentiate between developmentally regulated
apoptosis and apoptosis caused by MO off-targeting.
p53 MO Attenuates Off-Target Neural Death Induced by
MOs
The neural apoptosis induced by a variety of MOs and the
similarity to the phenotype induced by apparent p53
upregulation (Mdm2 MO) suggested the hypothesis that MO
off-target effects can induce the p53 apoptosis pathway.
Therefore, we tested whether p53 knockdown can rescue the
off-target apoptosis phenotype induced by several MOs.
Indeed, p53 MO attenuated the neural death induced by
smoothened and Wnt5 MOs, as shown by morphology (Figure
1D and 1F), acridine orange (unpublished data), and the more
speciﬁc TUNEL assay (Figure 2D and 2F). Similar results were
observed for p53 knockdown rescue of Mdm2 MO-induced
apoptosis (Figures 1N and 2M). Interestingly, p53 MO also
alleviated the neural death induced by the Wnt5 gripNA,
suggesting that this additional knockdown technology can
upregulate the p53 pathway due to off-targeting (Figures 1J
and 2I). However, as expected, p53 MO did not have any
effect on wnt5/ppt mutant embryos (Figures 1K, 1L, 2J, and
2K). A second p53 MO of independent sequence also
attenuated the off-target neural death, while a four-base
mismatched MO did not show any effect (unpublished data).
p53 MO as a Tool to Attenuate Neural Cell Death
Because neural death caused by MO-induced off-target
effects is so frequent [3,16], we tested the p53 MO as a tool to
alleviate off-target neural death. A good tool for this purpose
should be effective, innocuous, and speciﬁc. The p53 knock-
down by itself does not induce any signiﬁcant defects, as p53
is not required for normal development in mammals or ﬁsh
[17,18] (Figures 1B and 2B). Also, p53 MO does not affect the
efﬁcacy of gene-speciﬁc MOs, as it does not interfere with the
penetrance of gene-speciﬁc phenotypes. To further conﬁrm
this, we tested whether p53 MO can affect the efﬁciency of
splicing inhibition by Wnt5 MO1. Semi-quantitative reverse-
transcriptase PCR (RT-PCR) analysis of Wnt5 RNA tran-
scripts showed complete blockage of the splicing at exon 5–
exon 6 boundary targeted by Wnt5 MO1, which was not
affected by p53 MO (Figure 1H).
We also investigated whether p53 knockdown can affect
speciﬁc cell death (other than neural death) and whether it
affects phenotypes not associated with apoptosis (Figure 5).
As shown by morphology and TUNEL staining (Figure 5A–
5D), the p53 MO had no effect on the speciﬁc tail-cell death
induced by the loss of function of chordin using a chordin-
Figure 2. p53 MO Attenuates Apoptosis Induced by MOs and GripNAs,
as Detected by TUNEL Assay
(A–M) Fluorescent images of 30 hpf embryos injected with indicated
MOs and subjected to TUNEL assay to detect apoptosis. A strong
fluorescent signal for Smo MO (C), Wnt5 MO1 (E), and Wnt5 GripNA1 (H),
similar to Mdm2 MO (L), indicates increased apoptosis. The fluorescent
signal is strongly diminished by co-knockdown of p53 (D, F, I, and M),
similar to the uninjected control (A), Wnt5 MO2 (G), or Wnt5 mutant (J).
Wnt5 mutant is not affected by p53 knockdown (K).
doi:10.1371/journal.pgen.0030078.g002
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p53 Activation by Knockdown TechnologiesFigure 3. Temporal and Spatial Characterization of Representative MO-Induced Neural Cell Death during Early Embryogenesis
(A) Brightfield and darkfield images of Wnt5 MO1-injected embryos. 14 hpf (A–I), 22 hpf (J–R), and 30 hpf (S–AA). Uninjected embryos (A–C, J–L, and S–
U), intermediate cell death phenotype (D–F, M–O, and V–X), and severe cell death phenotype (G–I, P–R, and Y–AA). Lateral views (A, D, G, J, M, P, S, V,
and Y), all others dorsal head views. Intermediate cell death is observed at 14 hpf as highly localized opaque cells in the head (large arrow in D), which
are arranged near the lateral (arrowhead in E and F) and midline (small arrow in E and F) areas of the developing brain. This pattern progresses through
22 hpf and 30 hpf (M–O and V–X, respectively), including a concentration of opaque cells surrounding the emerging folds of the brain midline (small
arrows N–O and W–X) and the eye (arrowheads N–O and W–X). Severe cell death is observed as highly dense areas of opaque cells throughout the
developing head.
(B) TUNEL assay. Zebrafish embryos were injected with Wnt5 MO1 and analyzed by TUNEL assay at 14 hpf (A–F), 22 hpf (G–O), and 30 hpf (P–X) stages.
Uninjected embryos: A–C, G–I, and P–R. At the later time points two classes of phenotypes were observed: an intermediate (J–L and S-U) and a severely
affected class of embryos (M–O and V–X). These were characterized by intense fluorescent apoptotic foci in the head and body, with increasing intensity
corresponding to increased severity (higher MO dose). Please see Figure S1 for a higher resolution version of this figure.
doi:10.1371/journal.pgen.0030078.g003
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p53 Activation by Knockdown TechnologiesFigure 4. Representative Cell Death Phenotypes Detected at 26 hpf
Brightfield (A, B, D, E, G, H, J, and K) and darkfield images (C, F, I, and L) of 26 hpf zebrafish embryos injected with Wnt5 MO1. (M–X) TUNEL assay. Lateral
views (A, D, G, J, M, N, P, Q, S, T, V, and W), with inserts showing a higher magnification of the head region (A, D, G, and J). Dorsal view of the head (B, C,
E, F, H, I, K, L, O, R, U, and X). The two classes of phenotypes described in Figure 3 are observed at this time point, too (intermediate, G–I and P–R; severe,
J–L and S–T; uninjected embryos, A–C and M–O). At 26 hpf, however, a milder cell death phenotype was also observed (D–F). This class of embryos
exhibited an anterior-ventral concavity and a depressed hindbrain (indicated by the arrows), without tissue with obvious characteristic cell-death
patterns featured by embryos with intermediate and severe phenotypes (compare [F] to [I] and [L]). However, even these mildly affected embryos
showed clear apoptosis indicated by the TUNEL assay (P–R).
doi:10.1371/journal.pgen.0030078.g004
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p53 Activation by Knockdown Technologiesspeciﬁc MO. In addition, p53 knockdown showed no effect on
the MO-induced phenotypes of nacre (a pigment defect)
(Figure 5G and 5H), no tail (a developmental patterning gene)
(Figure 5I and 5J), or UROD (loss of function is visualized by
ﬂuorescence of red blood cells) (Figure 5K and 5L).
In conclusion, the p53 MO could be an efﬁcient tool to
attenuate off-target effects of MOs. We are currently
coinjecting the p53 MO with all the MOs tested in a large-
scale MO screen [16]. This strategy has greatly attenuated the
neural death phenotypes and has notably eased the inter-
pretation of the observed phenotypes, especially in cranio-
facial development (Figure 6; see below). p53 knockdown or
the use of p53 null zebraﬁsh [18] could potentially be of value
for use in more traditional genetic approaches, such as
chemical or insertional mutagenesis screens, to decrease the
collateral tissue damage due to p53-induced cell death that
potentially masks important phenotypes of particular inter-
est to investigators.
p53 MO as a Tool to Facilitate the Study of Craniofacial
Development
Early neural death and loss of neural tissue caused by MO
off-targeting could potentially affect later craniofacial devel-
opment. This may generate numerous false positives in MO
screening for genes important in craniofacial development.
For example, we tested whether p53 co-knockdown could
facilitate the analysis of craniofacial phenotypes, especially in
the cases of unknown genes or where corresponding mutants
are not available. For example, MOs that target three genes in
our collection of novel proteins [16], SP2035, SP2054, and
SP2063, caused neural death visible at 1 dpf and craniofacial
defects visualized by Alcian Blue staining of the cartilage at 4
dpf.
The neural death caused by these MOs was attenuated by
p53 co-knockdown (Figure 6A). The brightﬁeld panels in
Figure 6A show two types of milder neural defects that we
have described in Figure 4; an anterior-ventral concavity for
Figure 5. p53 MO Does Not Affect Specific Cell Death or Phenotypes Not Associated with Apoptosis
(A–B) Brightfield image of chordin morphant (3ng MO) injected (A) or not (B) with p53 MO (2 ng) (1 dpf).
(C–D) p53 MO does not affect the localized tail cell death, as also shown by the TUNEL assay (1 dpf).
(E–F) Brightfield images of 2 dpf uninjected embryo: lateral (E) and dorsal view (F).
(G–H) p53 MO (4 ng) does not affect (H) the lack of dorsal melanophores induced by nacre MO (9 ng) (G).
(I–J) no tail (3 ng) phenotype (I) is not affected by coinjection of 4 ng of p53 MO (J).
(K–L) UROD MO (9 ng) induces an autofluorescence of red blood cells (K). This phenotype is not affected by p53 MO coinjection (4 ng) (L) (1 dpf).
doi:10.1371/journal.pgen.0030078.g005
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p53 Activation by Knockdown TechnologiesFigure 6. p53 MO Attenuates Cell Death Induced by MOs against Novel Target Genes with Divergent Effects on Craniofacial Phenotypes
(A) Brightfield and fluorescent images of 1 dpf embryos injected with MOs targeted against three novel proteins: SP2054, SP2063 (two different MOs for
each target: MO1 and MO2), and SP2035. Brightfield images depict observed anterior morphological defects: anterior-ventral concavity (black arrows)
and depressed hindbrain (black arrowhead). Fluorescent images indicate areas of apoptosis visualized by live embryo acridine orange staining. Insets
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p53 Activation by Knockdown TechnologiesSP2054 and SP2063 (represented by a deﬁciency in the
frontonasal tissue development, black arrows in Figure 6A)
and a depressed hindbrain for SP2035 (represented by a lack/
developmental delay of the hindbrain tissue, black arrowhead
in Figure 6A). Interestingly, these milder defects were clearly
associated with neural apoptosis, as shown by acridine orange
staining (Figure 6A, ﬂuorescence panels and quantiﬁed in
corresponding graphs). At higher doses, the MOs against
these targets showed a clear cell death pattern even in
brightﬁeld images (represented by opaque structures; un-
published data).
Later in development (4 dpf), the MO-injected embryos
mentioned above also exhibited craniofacial defects (Figure
6B). We investigated whether these late craniofacial defects
were due to the early loss of neural tissue (off-targeting) or to
a speciﬁc role of the targeted genes in craniofacial develop-
ment. To achieve this, we analyzed the effect of p53 MO on
the cartilage structure at 4 dpf. The craniofacial defects in the
SP2035 and SP2054 MO-injected embryos were not affected
by p53 co-knockdown, while the craniofacial defects in the
SP2063 MO-injected embryo were signiﬁcantly diminished by
p53 co-knockdown (Figure 6C). These results suggest that
SP2035 and SP2054 are involved in craniofacial development,
while the craniofacial defects seen in SP2063 MO-injected
embryo are p53-dependent and thus may be due solely to off-
targeting effects of the MO.
To further distinguish putative roles of SP2035, SP2054,
and SP2063 in craniofacial development, we analyzed the
expression patterns of these genes in zebraﬁsh embryos
(Figures 7 and S2). At 1 dpf, all three genes were expressed in
the craniofacial region. But while the expression patterns of
SP2035 and SP2054 were spatially restricted, SP2063 was
more ubiquitously expressed. Interestingly, in subsequent
days of development, SP2035 and SP2054 transcripts became
speciﬁcally enriched in the pharyngeal arches primordia,
while SP2063 became restricted to central nervous system
structures (Figures 7 and S2). These expression patterns
support a direct role of SP2035 and SP2054 in craniofacial
development, while the role of SP2063 may be indirect, if any.
The CNS expression of SP2063 may also explain the partial
rescue of the SP2063 craniofacial phenotypes by p53 MO. If
brain structures were affected by SP2063 MO injection, this
may have inﬂuenced the mechanical structure of cartilage
and contributed to the craniofacial phenotype, in conjunc-
tion with the loss of neural tissue caused by MO off-targeting.
In conclusion, the likely involvement of the studied novel
genes in craniofacial development is supported by their
expression pattern and corroborated with the dependence of
craniofacial phenotypes on p53. Therefore, p53 co-knock-
down can be used to help clarify craniofacial phenotypes
induced by MOs against novel genes for which there are no
mutant data available for comparison.
p53 Pathway Is Induced in Morphants with Neural Death
To understand better the mistargeting effects of MOs, we
investigated other components of the p53 pathway. A direct
target of the p53 transcription factor is p21/WAF/CIP [19]. We
tested whether p21 transcription is induced in morphants
with neural death. Using quantitative RT-PCR, we observed a
signiﬁcant increase in p21 RNA levels in morphants that show
neural death (Smo MO and Wnt5 MO1) but no signiﬁcant
increase in morphants without off-target effects (Wnt5 MO2)
(Figure 8). Very importantly, this increase in p21 expression
was dependent on p53, since knockdown of p53 signiﬁcantly
decreased p21 RNA levels in respective morphants. Induction
of p21 levels provides direct evidence for activation of the
p53 protein. These results were similar to the induction of
p21 in Mdm2 MO-injected embryos, which was dependent on
p53, as expected (Figure 8) [14]. These results suggest that p53
protein is activated by injection of a selection of MOs,
associated with off-target neural apoptosis. Consistent with
this conclusion, p53 protein is not activated in a selection of
morphants that do not exhibit any neural death.
Transcriptional Regulation of p53 Does Not Contribute
Significantly to MO Off-Target Effects
Translational and post-translational mechanisms of p53
activation have been extensively documented [12]. A well-
known mechanism for p53 induction is due to Mdm2
inactivation. Because Mdm2 is a ubiquitin-E3 ligase that
targets p53 for proteasomal destruction, loss of function of
Mdm2 leads to p53 protein accumulation and consequent
apoptosis [14]. We investigated whether p53 transcriptional
regulation is part of the p53 induction due to MO off-
targeting. The p53 gene is known to express multiple
isoforms as result of alternative splicing and internal
promoters (Figure 9A) [20]. We designed primers to amplify
a fragment speciﬁc to full-length p53 cDNA, which is the
isoform we targeted by our p53 MO (Figure 9A) and was
shown to be sufﬁcient for neural death induction by co-
knockdown experiments (Figures 1 and 2). We examined the
levels of p53 transcription in embryos injected with various
MOs by semi-quantitative RT-PCR. Interestingly, there was
no signiﬁcant increase in full-length p53 RNA levels in
various MO-injected embryos (Figure 9B, top panel), suggest-
ing that transcriptional induction of full-length p53 does not
play a role in p53 activation by MO off-targeting. These
results, together with our observations that knockdown of
full-length p53 alleviates MO off-target effects, support a
direct role of full-length p53 protein, but not of p53
show a magnification of apoptotic foci in the head region. Upon p53 coinjection (þp53 MO), there is a significant attenuation of these phenotypes.
These results are quantitated for each target in the right graph panel.
(B) Brightfield images of 4.5 dpf embryos stained with Alcian Blue to visualize representative craniofacial phenotypes. Arrowheads indicate Meckel’s
cartilage (M), arrows indicate ceratohyal arch (Ch). Stars indicate the five branchial arches (Cb). Upon MO targeting of the three novel genes, two types
of craniofacial phenotypes were observed: mispatterning of the Meckel’s cartilage and ceratohyal (mispatterned phenotype), and loss of all branchial
arches, ceratohyal and severe hypoplasia of the Meckel’s cartilage (severe loss phenotype).
(C) Quantitation of the p53 MO effect on craniofacial phenotypes induced by MO targeting of three novel genes. Targeting of SP2054 with MO1
induced a high level of severe loss phenotype, while SP2054 MO2 showed mainly a mispatterned phenotype. None of these craniofacial phenotypes
were affected by p53 MO. SP2035 knockdown induced both types of craniofacial abnormalities and the proportion of these was not affected by p53 co-
knockdown. SP2063 MOs MO1 and MO2 induced a craniofacial mispatterning phenotype that was partially rescued by p53 MO, suggesting that this
craniofacial phenotype is a secondary effect of off-target neural death.
doi:10.1371/journal.pgen.0030078.g006
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targeting.
Diagnostic Transcriptional Induction of an N-Terminal
Truncated p53 Isoform in Morphants with Off-Target
Effects
The p53 locus expresses multiple transcripts as result of
alternative splicing and internal promoters [20]. For example,
zebraﬁsh have been recently reported to use an internal
promoter in intron 4, conserved from ﬂies to humans [21], to
express an N-terminal truncated form of p53, D113 p53
(Figure 9A) [22]. The truncated p53 isoform is highly
upregulated in zebraﬁsh def mutants, speciﬁcally in the
characteristic hypoplastic digestive organs [22].
We tested whether this truncated p53 isoform was induced
under cell-death conditions through MO off-targeting. To
discriminate between the two p53 transcripts, we designed
primers to amplify speciﬁcally either the full-length p53
cDNA or that encoding the truncated p53 isoform (Figure
9A) and used semi-quantitative RT-PCR to examine p53
transcripts (Figure 9B). While full-length p53 RNA levels were
not signiﬁcantly increased in any of the MO-injected embryos
(Figure 9B, top), the D113 p53 isoform was highly upregulated
in MO-injected embryos with neural death and virtually
absent in the MO-injected embryos with no neural death or
in the uninjected controls (Figure 9B, middle).
We also performed microarray screens for the transcrip-
tional consequences of various MOs. As shown in Figure 9C,
when zebraﬁsh embryos were treated with a MO or a gripNA
[11] against the D. rerio homolog of the fhit tumor suppressor
gene [23], we obtained evidence for increased transcription at
the p53 locus. In ﬁve fhit knockdown microarrays, p53
transcripts were increased 7.9-fold with respect to control-
injected embryos (t-test p-value ¼ 0.00007). Remarkably, p53
and two other mRNAs among the top eight transcripts
induced in the fhit datasets were common to the top eight
induced genes in def zebraﬁsh embryos [22]. Indeed, we have
seen many of the same mRNAs coinduced by unrelated MOs
(unpublished data). However, it is noteworthy that the probe
used for microarrays binds to the 39 UTR of p53, thus
recognizing both full-length and the D113 p53 isoforms
(Figure 9A).
We also conducted in situ hybridization experiments with a
p53 riboprobe in embryos injected with the two Wnt5 MOs,
one that showed neural death (MO1) and one that did not
Figure 7. Expression Patterns of SP2035, SP2054, and SP2063
In situ hybridization for SP2054, SP2035, and SP2063 showed that all three transcripts were localized in anterior structures prior to chondrogenesis( 1
dpf). Later in development, SP2054 and SP2035 transcripts became localized in pharyngeal arch structures during cartilage formation (2 dpf, see Figure
S2; and 3 dpf), while SP2063 mRNA was expressed in brain structures.Please see Figure S2 for a higher resolution version that also includes a 2 dpf time
point.
AB, anterior brain; CNS, central nervous system; MHB, midbrain/hindbrain boundary; OS, optic stalk; PA, pharyngeal arch; V, vasculature.
doi:10.1371/journal.pgen.0030078.g007
Figure 8. Quantitative RT-PCR of p21/WAF/CIP in Various Morphants
p21 RNA levels were significantly increased in MO-injected embryos that
showed neural death (Smo MO, Wnt5 MO1, and Mdm2 MO) as compared
to the uninjected control (UI). Interestingly, p21 levels were not
significantly altered by Wnt5 MO2 (which does not induce neural death).
Very importantly, p21 levels were significantly reduced in the respective
MO-injected embryos upon p53 co-knockdown (Mdm2 MO p , 0.01,
Wnt5 MO2 p , 0.01, Smo MO p , 0.002; t-test p values for unpaired
sets), strongly suggesting that p21 is transcriptionally upregulated by
p53 in the morphants with neural death. Error bars indicate standard
deviation.
doi:10.1371/journal.pgen.0030078.g008
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p53 Activation by Knockdown TechnologiesFigure 9. p53 Isoforms Expression in Various MO-Injected Embryos
(A) Schematic of p53 and D113 p53 transcripts. The p53 gene contains 11 exons (indicated by numbered rectangles), with the two promoters P1 and P2
indicated by the arrows. Transcription initiation at promoter P1 in exon 1 generates the full-length p53 transcript. D113 p53 transcript is initiated at an
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p53 Activation by Knockdown Technologies(MO2) (Figure 9D). Wnt5 MO1 showed increased p53 mRNA
expression in the anterior part of the body (arrow, Figure
9D), while Wnt5 MO2 showed low ubiquitous p53 mRNA
expression similar to the uninjected control (Figure 9D). In
this case also, the riboprobe could bind both full-length and
the D113 p53 isoforms (Figure 9A).
The RT-PCR experiments in Figure 9B showed that full-
length p53 RNA levels were not increased in any MO-injected
embryos, while the D113 p53 isoform was highly induced in
embryos injected with off-targeting MOs. These results
suggest that the increased p53 expression observed by
microarray and in situ hybridization consists largely of
D113 p53 RNA, and that transcriptional induction of full-
length p53 does not contribute to p53 activation by MO off-
targeting.
Does Increased Transcription of the Shortened p53
Isoform Cause the MO Off-Targeting Cell Death?
The p53 MO, which blocks neural cell death, was designed
to knock down full-length p53 and would not be expected to
affect the D113 p53 isoform (Figure 9A). To further test
whether the highly induced D113 p53 mRNA is required for
neural cell death, we designed a translational MO to
speciﬁcally knock down this isoform (Figure 9A). We cannot
design a splice-site blocker MO speciﬁc only for the N-
terminal truncated isoform because all the splice junctions
present in D113 p53 are also present in full-length p53
(Figure 9A). Coinjection of the D113 p53 MO with off-
targeting MOs did not block cell death (unpublished data).
This result is consistent with the fact that D113 p53 lacks the
transactivation domain and part of the DNA binding domain,
which are thought to be required for induction of apoptosis
[21]. Thus, the D113 p53 isoform is most likely not the cause
of cell death induced by MOs and may represent a diagnostic
signature of off-target effects. In contrast, the full-length p53
protein is sufﬁcient to cause neural death due to MO off-
target effects, even if transcript levels are unchanged. More
experiments are necessary to evaluate the signiﬁcance of the
D113 p53 isoform transcriptional induction beyond its use as
a diagnostic for p53 activation.
Discussion
Mechanism of Off-Target Effects
We have shown that mistargeting MOs induce neural death
via a pathway involving p53 activation. Curiously, ongoing
synthesis of full-length p53 is required for cell death, while
transcription of the D113 p53 isoform is a consistent and
striking component of the mistargeting MO signature. We
investigated various hypotheses for the mechanism under-
lying this off-target effect. The p53 pathway induction is
independent of the intended gene target and appears to be
sequence-speciﬁc, since two MOs of independent sequence,
but targeted to the same gene, have strikingly different effects
on p53 induction. This off-target effect is noted in both
translational blockers and splice-site MOs, suggesting that the
mechanism does not uniquely involve the transcription or the
translation machinery. According to our analysis, MOs with
off-target effects do not exhibit any overt primary sequence
similarity to repeated elements such as rRNA genes or the
zebraﬁsh mitochondrial genome (unpublished data).
Although the mechanism of MO-induced p53 activation is
still unclear, this pathway is activated by other knockdown
technologies including gripNAs (Figures 1I and 1J, 2H and 2I,
and 9C). Furthermore, related observations indicate that
siRNAs can also induce off-target p53 activation. A recent
study reports divergent changes in levels of p53 and p21 in
cells subjected to ten different siRNAs targeted to menin [4].
The study shows that, while all the siRNAs knock down menin
levels to various extents, some of the siRNAs cause a
signiﬁcant increase in p53 and p21 protein levels, independ-
ent of the levels of menin knockdown, while others have no
effect on p53 or p21. One hypothesis is that the off-target
effects caused by siRNAs are due to short sequence homology
to other genes [5–7,24]. We have not observed any pattern of
partial homology between off-targeting MOs and p53 or
Mdm2 genes (unpublished data).
Diagnostic Transcriptional Activation of a Shorter Isoform
of p53
We have shown that certain MOs and gripNAs induce
neural cell death in a manner that depends on synthesis of
full-length p53 protein, but not on transcriptional activation
of full-length p53. We also observed a diagnostic transcrip-
tional induction of an N-terminal truncated isoform of p53.
Interestingly, this truncated form is thought to act as a
dominant negative molecule towards full-length p53, as it
lacks the transactivation domain and part of the DNA
binding domain [21]. The human homolog of D113 p53 was
shown to be defective in promoting apoptosis and even to
inhibit p53-mediated apoptosis [21].
Consistent with these results, a translational MO targeted
internal promoter in intron 4, P2, and contains the 39 end of intron 4 (indicated by the yellow rectangle), and likely uses the Met at position 113 as
translational start (red bar) [22]. Translation start sites for the two transcripts are indicated by the red bars (in exon 2 for P1; putative translation start in
exon 5 for P2, corresponding to Met 113). Translational MO binding sites for the two isoforms are indicated by orange stars. The MO for full-length p53
most likely does not affect the D113 p53 transcript, as its binding site is 386 nt upstream of the translational start for the D113 p53 transcript. The
fragments amplified for the RT-PCR experiments are indicated by the blue bars and are specific to each isoform. The riboprobe fragment for in situ
hybridization (indicated by the green bars) and the microarray probe binding site (indicated by the purple bars) are common to both isoforms.
(B) RT-PCR for full-length p53 and D113 p53. Final products of 30 cycles of RT-PCR for D113 p53 were analyzed by gel electrophoresis on a 1% agarose
gel, stained with ethidium bromide. b-actin was used as loading control. There is no significant upregulation of full-length p53 expression levels in
various morphants. Note the lack of expression of D113 p53 in uninjected embryos or morphants with no neural death. Embryos injected with MOs that
cause neural death show a significant increase of D113 p53 isoform expression.
(C) Transcripts induced by fhit knockdown in microarray assays. Fold increases in mRNA accumulation and t-test p values were calculated from the three
control (phenol red-injected) intensities and the five experimental intensities determined in eight independent hybridizations using printed 16,399
element 65mer microarrays. The first three experimental samples were embryos injected with the gripNA targeting fhit while the fourth and fifth
experimental samples were Fhit morphants. NCBI unigene identifiers are for the D. rerio genes. Gene symbols correspond to human orthologs. The
three transcripts common to the top eight induced transcripts in fhit and def [22] datasets are indicated.
(D) p53 in situ hybridization. Expression of p53 transcripts is increased in the anterior part of the embryo (indicated by the arrow) upon injection of
Wnt5 MO1 (that causes neural death), but not in the morphant with no neural death (Wnt5 MO2).
doi:10.1371/journal.pgen.0030078.g009
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p53 Activation by Knockdown Technologiesspeciﬁcally to the D113 p53 isoform did not alleviate the
neural death induced by off-targeting MOs (unpublished
data), although the full-length p53 knockdown did. Also,
overexpression of D113 p53 RNA in zebraﬁsh embryos did
not cause neural death (unpublished data), suggesting that the
D113 p53 isoform is insufﬁcient to promote apoptosis.
Potentially, the D113 isoform is transcriptionally induced
secondary to p53-mediated apoptosis.
Transcriptional induction of the D113 isoform of p53 may
represent a diagnostic signature for a speciﬁc type of cellular
stress. High levels of the D113 isoform p53 transcription were
observed in def [22] and fhit knockdown embryos and in
morphants with off-targeting phenotypes, while lower levels
of mRNA increase were observed in ﬂathead embryos [25]. It
remains to be determined whether off-targeting oligos target
DNA, an RNA other than mRNA, or another cellular
component, and whether the fhit knockdown proﬁle is due
to off-targeting or to a speciﬁc involvement in the stress
response pathway.
A previous study also reported the presence of a shorter
p53 transcript in zebraﬁsh [14], with a size consistent with the
predicted length of the D113 p53 isoform. Intriguingly, this
shorter transcript was highly upregulated in zebraﬁsh
embryos under cell death–inducing conditions such as treat-
ment with camptothecin or roscovitine or knockdown of the
anti-apoptotic genes mdm2 and tsg1. Also noteworthy, the
expression of the shorter p53 transcript seemed to be
dependent on full-length p53 [14].
Specific versus Off-Target Neural Death
A very important issue for using p53 knockdown to
mitigate neural death is speciﬁcity. In many cases, neural
death can be a speciﬁc phenotype, and p53 MO rescue may
suggest a speciﬁc interaction with the gene of interest. A key
experiment to validate a MO phenotype is to observe rescue
of the morphant phenotype with an RNA or DNA construct
of the respective gene. If the neural death is rescued by the
RNA/DNA construct, it is very likely that the gene of interest
is speciﬁcally involved in cell death. If, however, the RNA/
DNA rescue still yields a neural death phenotype, it is possible
that the neural death is an off-target effect of the MO. For
example, a recent study reported apoptosis and neuronal loss
upon knockdown of presenilin enhancer Pen-2 in zebraﬁsh
embryos [26]. This neural death was signiﬁcantly reduced by
p53 co-knockdown, as in the case of off-targeting MOs.
However, the authors clearly showed a rescue of the neural
apoptosis by a Pen-2 RNA construct of a sequence not
overlapping with the Pen-2 MO [26]. Together, these results
support a true anti-apoptotic role of Pen-2 in promoting
neuronal survival.
We have also attempted to rescue the Mdm2 MO-induced
cell death phenotype with a Mdm2 RNA construct. However,
we did not observe any signiﬁcant rescue (unpublished data).
One potential explanation is that this particular Mdm2 MO
also has off-targeting effects. Five additional Mdm2 MOs have
been reported to cause cell death that could be rescued by
p53 MO [14], but we did not test any of these. We also tested
whether the Wnt5 MO1-induced cell death is wnt5/ppt speciﬁc
or a result of off-targeting. There are no indications from
previous studies to suggest a role of wnt5/ppt in cell death. We
observed no effect of a wnt5/ppt RNA construct [27] on the cell
death speciﬁcally induced by Wnt5 MO1 (unpublished data),
but not by Wnt5 MO2. However, we did not observe any
rescue of the characteristic morphological defect associated
with loss of wnt5/ppt either. This result is not so surprising,
though, as there is no previous report on a successful RNA
rescue of the body axis shortening phenotype caused by wnt5/
ppt inactivation (either mutation- or MO-induced). It is
possible that generalized overexpression of wnt5/ppt RNA
may not be sufﬁcient to compensate for decreased wnt5/ppt
levels at the appropriate time and place.
In conclusion, if a cell-death phenotype caused by knock-
down can be rescued by the respective RNA/DNA construct, it
is likely that the gene of interest is involved in cell survival. If
the RNA/DNA construct rescues the gene-speciﬁc phenotype
but does not rescue the cell death phenotype observed in
MO-injected embryos, it is likely that cell death represents an
off-targeting effect of the MO. It is also possible that certain
MO-induced phenotypes cannot be rescued by corresponding
RNA/DNA overexpression, due to improper localization and/
or timing of expression during development.
Ongoing work is geared to exploit p53 co-knockdown to
alleviate off-target neural death of MOs and to discover the
mechanism by which off-target MOs induce p53 activation as
well as the signature D113 p53 transcript. Potentially, p53
knockdown by RNAi may also alleviate the off-target effects
of siRNAs [7].
Materials and Methods
Fish maintenance. Wild-type zebraﬁsh were purchased from
Segrest farms (http://www.segrestfarms.com). Embryos were raised at
30 8C and spawning was carried out as described [28]. wnt5 mutant
ﬁsh carrying the ppt
hi1789b allele [29] were obtained from the
Zebraﬁsh International Resource Center (http://zebraﬁsh.org/zirc).
MO and gripNA sequences and injections. MO and gripNA
sequences are shown in Table 1. MOs were obtained from Gene
Tools (http://www.gene-tools.com) and were prepared and injected in
1–4 cell stage embryos as described [30]. When two MOs were injected
in the same embryo, we carried out both separate injections of the
different MOs and single injections of MO mixtures, with very similar
results. The only difference was a slightly increased mortality in the
case of double-injected embryos as compared to single injections. In
all cases, except where noted, p53 MO was injected 1.5-fold (w/w) to
the other MO used. MO doses were: 3 ng of Smo MO, Wnt5 MO1, and
Mdm2 MO; 4.5ng of p53 MO (except where noted otherwise); and 6ng
of Wnt5 MO2. GripNAs were obtained from Active Motif (http://www.
activemotif.com) and were prepared and injected similar to MOs.
Wnt5 GripNA was injected at 2.25 ng, and coinjections with p53 MO
were at 4 ng.
Embryos were visualized at 24–29 hpf, except where noted.
Microscopy was performed on a Zeiss Axioplan 2 microscope
(http://www.zeiss.com) ﬁtted with differential interference contrast
microscopy optics. Images were captured with a Nikon Coolpix 995
(http://www.nikonusa.com) or a Canon PowerShot G6 digital camera
(http://www.canon.com), with multiple images combined using Adobe
Photoshop software (http://www.adobe.com).
TUNEL assay. Embryos were dechorionated and ﬁxed at 30 hpf or
as indicated in 4% paraformaldehyde for 1 h at room temperature.
They were then washed with PBS buffer twice and permeabilized with
0.1% sodium citrate and 0.1% TritonX for 2 min on ice. After
washing twice in PBS buffer, embryos were incubated with the
reaction mixture containing the terminal deoxynucleotidyl trans-
ferase and TMR-labeled nucleotides for 1 h in the dark at 37 8C.
Reaction was stopped by washing with PBS three times. Terminal
deoxynucleotidyl transferase catalyzes incorporation of labeled
nucleotides to 39-OH DNA ends in a template-independent reaction.
The ﬂuorescent signal was visualized and imaged using a Zeiss
Axioplan 2 microscope coupled to an ApoTome, using AxioVision 4.2
software. z-stacks were superimposed using Extended Focus feature
of the software.
Acridine orange assay. Live embryos were immersed in 5 lg/ml
acridine orange (Sigma, http://www.sigmaaldrich.com) for 10 min,
then visualized and imaged for less than 60 s (the signal is quenched
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assay.
Quantitative RT-PCR. Total RNA was extracted from 32 hpf
embryos using TRIZOL reagent (Invitrogen, http://www.invitrogen.
com). Quantitative RT-PCR was carried out on 200ng of RNA using
the LightCycler RNA Ampliﬁcation kit SYBR Green (Roche, http://
www.roche-diagnostics.us) in a LightCycler 2.0 Instrument, following
manufacturer’s protocols. The primers used are shown in Table 2. All
expected PCR products span at least one intron (except the D113 p53
fragment), to ensure ampliﬁcation solely from the cDNA and not
from the genomic DNA. The primers for full-length p53 correspond
to exon 4 (not present in the D113 p53 isoform) and exon 5. The
primers for the D113 p53 isoform correspond to intron 4 (not present
in the full length p53) and exon 5. The identity of the RT-PCR
products was conﬁrmed by sequencing. The samples were quantiﬁed
by comparative cycle threshold (Ct) method for relative quantiﬁca-
tion of gene expression [31], normalized to b-actin. All experiments
were performed with at least two different RNA preparations and at
least three independent experiments for each RNA preparation.
In situ hybridization. cDNA for p53 probe was ampliﬁed using
total RNA from 24 hpf zebraﬁsh embryos injected with pax2 MO
(Table 1) with primers shown in Table 2. The p53 riboprobe used in
the in situ hybridization experiments spans exons 6–11, a region
common to both full-length and D113 p53 isoforms. The cDNAs for
SP2035, SP2054, and SP2063 were ampliﬁed from total RNA from 30
hpf zebraﬁsh embryos, using primers indicated in Table 2. The PCR
fragments for p53, SP2035, SP2054, and SP2063 were cloned into the
pCRII TOPO vector (Invitrogen). The plasmids were then linearized
with NotI (p53, SP2054 and SP2063) or Spe I (SP2035). DIG-labeled
antisense RNA was synthesized using the SP6 polymerase (p53,
SP2054, and SP2063) or T7 polymerase (SP2035) in conjunction with
the in vitro DIG labeling kit (Roche). Zebraﬁsh in situ hybridization
was performed on 26–28 hpf embryos or indicated time points as
previously described [32]. Microscopy was performed on a Zeiss
Axioplan 2 microscope using DIC optics. Images were captured with a
Canon PowerShot G6 digital camera.
Alcian Blue cartilage staining. Cartilage was stained with Alcian
Blue using a modiﬁcation of previously published protocols [33,34].
Anesthetized 4.5 dpf larvae were ﬁxed in 4% phosphate-buffered
paraformaldehyde overnight at 4 8C, then stained with 0.1% Alcian
Blue (Sigma) in 70% ethanol and 0.37% hydrochloric acid for 4–6
hours at 4 8C. The embryos were cleared in 70% ethanol and 0.37%
hydrochloric acid mixture, then rehydrated stepwise in PBS buffer.
To enhance optical clarity, embryos were bleached with 3% H2O2
and 1% KOH for 20 min, then washed with PBS containing 0.2%
Tween-20, then with PBS, and lastly with H2O. Embryos were stored
in 50% glycerol with 0.25% KOH at 4 8C and were mounted in 2%
methylcellulose for imaging.
Table 1. MO Sequences
MO Name MO Type MO Sequence Reference
p53 MO Translational blocker (ATG) GCGCCATTGCTTTGCAAGAATTG [14]
2
nd p53 MO Translational blocker (ATG) GACCTCCTCTCCACTAAACTACGAT This paper
Mismatch p53 MO Translational blocker (ATG) GCaCCATcGCTTgGCAAGcATTG [14]
Smo MO Translational blocker (ATG) CGCTTGGAGGACATCTTGGAGACGC This paper
Wnt5 MO1 Splice-site–exon 6 splice acceptor (exon 5–6 junction) TGTTTATTTCCTCACCATTCTTCCG [27]
Wnt5 gripNA1 Splice-site—exon 6 splice acceptor (exon 5–6 junction) TTCCTCACCATTCTTCCG This paper
Wnt5 MO2 Splice-site–exon 5 splice donor (exon 4–5 junction) CACCAGGTCAACTCACCTATATGCA Kim and Ekker, unpublished
Mdm2 MO Translational blocker (ATG) CTCTGTTGCCATTTTGGTAGTTATC [14]
chordin MO Translational blocker (ATG) ATCCACAGCAGCCCCTCCATCATCC [30]
nacre MO Translational blocker (ATG) CATGTTCAACTATGTGTTAGCTTCA [30]
no tail MO Translational blocker (ATG) GACTTGAGGCAGGCATATTTCCGAT [30]
UROD MO Translational blocker (ATG) GAATGAAACTGTCCTTATCCATCA [30]
pax2 MO Translational blocker (ATG) CATGGATAGCAAAGGAAGGAAAGA [3]
SP2035 MO Translational blocker (ATG) ATAAAACAGAGATGGATGAAGATGC [16]
SP2054 MO1 Translational blocker (ATG) GAAGTCCTTGTCTTGTGTGGAGCAA [16]
SP2054 MO2 Translational blocker (ATG) CCGTAGTAGAAATTGCTGCCATGAC [16]
SP2063 MO1 Translational blocker (ATG) ATGGTAACTTGTCTCGTCTCCTTGA [16]
SP2063 MO2 Translational blocker (ATG) TGAAAGGAACGCTCGGTAATATATG [16]
Fhit MO Translational blocker (ATG) CCATAGTGGAGAATCAATTTCTTGA This paper
Fhit gripNA Translational blocker (ATG) CCATAGTGGAGAATCAAT This paper
doi:10.1371/journal.pgen.0030078.t001
Table 2. Primer Sequences
Primer
Name
Primer
Sequence
Fragment
Length (nt)
GeneBank
Accession
Number
Reference
p53 forward/p53 reverse CTCTCCCACCAACATCCACT/ACGTCCACCACCATTTGAAC 178 NM 131327
p21 forward/p21 reverse CGGAATAAACGGTGTCGTCT/CGCAAACAGACCAACATCAC 213 AL 912410 [22]
b-actin forward/b-actin reverse CCCAGACATCAGGGAGTGAT/TCTCTGTTGGCTTTGGGATT 239 NM 131031
D113 p53 forward/D113 p53 reverse ATATCCTGGCGAACATTTGG/ACGTCCACCACCATTTGAAC 214 NM 131327 [22]
p53 forward probe/p53 reverse probe TTGTCCCATATGAAGCACCA/GGGCTCAGATGATTCACGAT 515 NM 131327
Wnt5 exon5/Wnt5 exon6 GGGTGTTGTGAATGCTGTGA/CTGAGACGCCATGACACTTG 302 NM 130937
SP2035 forward/SP2035 reverse TCCCCATTCCAGCTCTCCAACC/TCTCAACTGGGTCCAAGGTG 1015 NM 131401 [16]
SP2054 forward/SP2054 reverse CGCGGTAAAACACATTTTGCTG/TATCAGCGATCACAAAGTTAACT 719 BX 901879 [16]
SP2063 forward/SP2063 reverse CCTCGTTTGCTGTCATATATTACCG/GTTGAACCGTTCCTTTAATCTGTAC 850 NM 199847 [16]
doi:10.1371/journal.pgen.0030078.t002
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p53 Activation by Knockdown TechnologiesMicroarrays. Transcriptional proﬁling was performed by the
Thomas Jefferson University Microarray Facility at the Kimmel
Cancer Center. The spotted array contains 16,399 oligonucleotides
(Compugen; annotated at http://giscompute.gis.a-star.edu.sg/;govind/
zebraﬁsh/version2). More than 100 b-actin oligonucleotides that serve
as positive controls were present on each chip.
Zebraﬁsh embryos were injected with phenol red control or 0.5 nl
of 1 mM Fhit MO or 1 nl of 1 mM Fhit gripNA. Total RNA of 24 hpf
phenol red control and MO-injected embryos were extracted by
TRIZOL (Invitrogen). Gene expression was determined using biotin-
labeled and in vitro–transcribed antisense RNA generated from the
total RNA template. Each chip was scanned and quantiﬁed using a
ScanArray Express laser scanner (PerkinElmer, http://www.
perkinelmer.com). The signals on the oligo microarray were
normalized by the median and regularized t-test was performed to
determine signiﬁcant differences between the controls and mor-
phants. The p53 probe used in the microarrays corresponds to a short
EST in the 59 UTR of the gene (U60804) and consequently is common
to both full-length and the D113 p53 isoform.
Supporting Information
Figure S1. Temporal and Spatial Characterization of Representative
MO-Induced Neural Cell Death during Early Embryogenesis
(A) Brightﬁeld and darkﬁeld images of Wnt5 MO1-injected embryos.
14 hpf (A–I), 22 hpf (J–R), and 30 hpf (S–AA). Uninjected embryos (A–
C, J–L, and S–U), intermediate cell death phenotype (D–F, M–O, and
V–X), and severe cell death phenotype (G–I, P–R, and Y–AA). Lateral
views (A, D, G, J, M, P, S, V, and Y), all others dorsal head views.
Intermediate cell death is observed at 14 hpf as highly localized
opaque cells in the head (large arrow in D), which are arranged near
the lateral (arrowhead in E and F) and midline (small arrow in E and
F) areas of the developing brain. This pattern progresses through 22
and 30 hpf (M–O and V–X), including a concentration of opaque cells
surrounding the emerging folds of the brain midline (small arrows N–
O and W–X) and the eye (arrowheads N–O and W–X). Severe cell
death is observed as highly dense areas of opaque cells throughout the
developing head.
(B) TUNEL assay. Zebraﬁsh embryos were injected with Wnt5 MO1
and analyzed by TUNEL assay at 14 hpf (A–F), 22 hpf (G–O), and
30hpf (P–X) stages. Uninjected embryos: A–C, G–I, and P–R. At the
later time points two classes of phenotypes were observed: an
intermediate (J–L and S–U) and a severely affected class of embryos
(M–O and V–X). These were characterized by intense ﬂuorescent
apoptotic foci in the head and body, with increasing intensity
corresponding to increased severity (higher MO dose). This ﬁgure
represents a higher resolution version of Figure 3.
Found at doi:10.1371/journal.pgen.0030078.sg001 (5.4 MB TIF).
Figure S2. Expression Patterns of SP2035, SP2054, and SP2063
In situ hybridization for SP2054, SP2035, and SP2063 showed that all
three transcripts were localized in anterior structures prior to
chondrogenesis (1 dpf). Later in development, SP2054 and SP2035
transcripts became localized in pharyngeal arch structures during
cartilage formation (2 dpf and 3 dpf), while SP2063 mRNA was
expressed in brain structures.
AB, anterior brain; CNS, central nervous system; MHB, midbrain/
hindbrain boundary; OS, optic stalk; PA, pharyngeal arch; V ¼
vasculature.
Found at doi:10.1371/journal.pgen.0030078.sg002 (9.5 MB TIF).
Accession Numbers
Accession numbers for the genes and gene products from the
Ensembl D. rerio genome database (http://www.ensembl.org/
Danio_rerio/index.html) are b-actin, NM 131031; chordin, NM
130973; Mdm2, NM 131364; nacre, NM 130923; no tail, NM 131162;
p21, AL 912410; p53, NM 131327; pax2, NM 131184; smoothened, NM
131027; SP2035, NM 131401; SP2054, BX 901879; SP2063, NM 199847;
UROD, NM 131347; and wnt5, NM 130937.
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